Kathleen Myers

Title: Innovations by Kathleen Myers

Introduction

Kathleen Myers is a notable inventor based in Oceanside, CA. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have potential therapeutic applications. With a total of 2 patents, her work focuses on enhancing the efficacy and safety of existing medications.

Latest Patents

One of her latest patents is titled "Analogs of dextromethorphan with balanced receptor activities." This patent discloses substituted analogs of dextromethorphan (DM) that exhibit substantial binding affinity at both NMDA and sigma-1 receptors. These analogs are designed to be degraded by human liver enzymes more slowly than dextromethorphan, making them useful alternatives that can provide similar benefits without the need for co-administration of a cytochrome P-450 enzyme inhibitor. Another significant patent is "Modulation of RANKL expression," which provides compounds, compositions, and methods for modulating the expression of RANKL. The compositions include oligonucleotides targeted to nucleic acid encoding RANKL, with methods for using these compounds for diagnosis and treatment of diseases associated with RANKL expression.

Career Highlights

Throughout her career, Kathleen has worked with prominent organizations such as Isis Pharmaceuticals, Inc. and the Center for Neurologic Study. Her experience in these companies has allowed her to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Kathleen has collaborated with esteemed colleagues, including Brenda F. Baker and C. Frank Bennett. These partnerships have further enriched her research and innovation efforts.

Conclusion

Kathleen Myers is a pioneering inventor whose work in pharmaceuticals has the potential to transform treatment options for various conditions. Her innovative patents and collaborations highlight her commitment to advancing medical science.